Growth Accelerated By Increased Prevalence Of Swine Fever, The Global Swine Fever Vaccine Market To Exhibit Increasing Growth In The Coming Years

cmisamruddhi12

I am cmisamruddhi12. I hold full responsibility for this content, which includes text, images, links, and files. The website administrator and team cannot be held accountable for this content. If there is anything you need to discuss, you can reach out to me via samruddhi@coherentmarketinsights.com email.

Disclaimer: The domain owner, admin and website staff of Times Square Reporter, had no role in the preparation of this post. Times Square Reporter, does not accept liability for any loss or damages caused by the use of any links, images, texts, files, or products, nor do we endorse any content posted in this website.

African swine fever (ASF) is a severe viral disease affecting domestic and wild pigs. Wide use of swine fever vaccine can effectively block the transmission of ASF virus, offering immunity to pigs. The vaccine helps prevent economic losses to farmers and safeguards the local pork supply. The vaccine consists of live attenuated ASF virus that produces high-level, long-lasting immunity with a single dose administration. The global swine fever vaccine market provides effective prevention against the widespread African swine fever disease. An increasing number of pigs being vaccinated annually in order to control the highly contagious virus that affects swine populations.

The global swine fever vaccine market is estimated to be valued at US$2885.25 million in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
The increasing prevalence of African swine fever among pig farms has resulted in massive economic losses, subsequently driving demand for effective swine fever vaccines. As per data, China lost over a third of its pig population due to the ASF outbreak in 2018. Several initiatives taken by governments and international organizations to curb the spread of the disease has further boosted adoption. Industry players are focusing on developing improved live attenuated vaccines with high immunogenicity and safety. Rising livestock agriculture in developing nations also acts as a growth catalyst. However, stringent regulations pertaining to vaccine development may hinder market growth over the forecast period.

Segment Analysis
The global swine fever vaccine market is segmented by technology into attenuated live vaccine, killed vaccine and subunit vaccine. This is because subunit vaccines are made from purified antigen which reduces the risk of reverting to virulence, making them very safe to produce compared to live or inactivated vaccines.

Key Takeaways
The Global Swine Fever Vaccine Market Trend is expected to witness high growth over the forecast period of 2023 to 2030. The market size is projected to increase from US$ 2885.25 Mn in 2023 registering a CAGR of 5.9% during the forecast period.

Regional analysis
The Asia Pacific region currently dominates the global swine fever vaccine market with a share of around 45% due to rising number of hog farms in major swine producing countries of China and Vietnam. The regional market is expected to witness the fastest growth over the forecast period supported by various government initiatives to prevent outbreaks of African swine fever virus.

Key players
Key players operating in the swine fever vaccine market include Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd., Bioveta, a.s., Komipharm, and EC21 Inc. Merck & Co. dominates the market with its DIVA-differentiable marker vaccines providing an efficacious and safe option for differentiating infected from vaccinated animals.

For more insights, read- https://www.dailyprbulletin.com/rising-incidence-of-african-and-classical-swine-fever-diseases-size